Ipamorelin vs CJC-1295: Research Comparison | Peptide Intel Hub

Ipamorelin is a pentapeptide selective agonist at the ghrelin receptor (also known as the GHS-R1a or growth-hormone secretagogue receptor). Its proposed mechanism in research models is selective ghrelin-axis activation without meaningful effect on cortisol, prolactin or aldosterone release — which distinguishes it from earlier ghrelin-receptor agonists.

CJC-1295 is a 30-residue GHRH analogue acting at the GHRH receptor. The 'with DAC' variant adds a drug-affinity-complex modification that promotes covalent albumin binding and substantially extends the half-life; the 'no DAC' variant is the unmodified short analogue.

Ipamorelin is selective for the ghrelin receptor — the selectivity profile is the engineering advantage over earlier ghrelin-receptor agonists like GHRP-6 or GHRP-2 which carry additional off-target effects.

CJC-1295 is selective for the GHRH receptor. The complementary receptor profile to ipamorelin is the reason the two are typically paired in research panels — combined ghrelin-axis and GHRH-axis activation produces a synergistic GH-release signal in research models.

Ipamorelin has a short native half-life — research cadences in published preclinical work are typically daily or sub-daily.

CJC-1295 no DAC sits in a similar daily-cadence window; CJC-1295 with DAC has a substantially longer half-life (multi-day) driven by covalent albumin binding through the DAC modification, suitable for weekly research cadences.

Ipamorelin is used in research models of ghrelin-axis signalling, growth-hormone-axis research and selective-secretagogue-comparator studies. The clean selectivity profile makes it the reference compound for ghrelin-receptor research.

CJC-1295 (with or without DAC) is used in research models of GHRH-axis signalling, growth-hormone-axis research, and as the GHRH-arm in combined-axis panels with ipamorelin. The DAC variant is preferred when a sustained multi-day GHRH-axis signal is the experimental requirement.

Both Ipamorelin and CJC-1295 ship from Regena Peptides only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena Peptides lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena Peptides COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Ipamorelin and CJC-1295 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose ipamorelin when the protocol targets selective ghrelin-receptor signalling without GHRP-6 / GHRP-2 off-target effects. Researchers choose CJC-1295 when the protocol targets the GHRH axis specifically — no DAC for a pulsatile profile, with DAC for a sustained multi-day profile. Matched panels of ipamorelin + CJC-1295 are one of the most common growth-hormone-secretagogue research designs.

For multi-compound comparator studies, the Regena Peptides consultations team will reserve matched-batch inventory of both Ipamorelin and CJC-1295 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Ipamorelin and CJC-1295 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena Peptides site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.